Asher Biotherapeutics, also known as Asher Bio, is a biotechnology company developing immunotherapies intended for cancer, autoimmune disorders, and infectious diseases. Asher Biotherapeutics was founded in 2019 by Ivana Djuretic and Andy Yeungand and is headquartered in San Francisco, CA. The company is committed to creating new treatment paradigms by using its proprietary cis-targeting platform to engineer therapies that selectively engage immune cells.
Asher Biotherapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Asher Biotherapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Asher Biotherapeutics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
---|---|---|---|---|
4/16/2024 | Series C | $55MM raised | $XXX.XX | $XXX.XX |
9/1/2021 | Series B | $108MM raised | $XXX.XX | $XXX.XX |
3/23/2021 | Series A | $55MM raised | $XXX.XX | $XXX.XX |
8/19/2019 | Series Seed-1, Seed-2 and Seed-3 | $3.65MM raised | $XXX.XX | $XXX.XX |